{"id":"NCT01792518","sponsor":"Boehringer Ingelheim","briefTitle":"MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin","officialTitle":"A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2015-11","completion":"2015-12","firstPosted":"2013-02-15","resultsPosted":"2017-03-06","lastUpdate":"2017-03-06"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Linagliptin 5mg","otherNames":[]}],"arms":[{"label":"linagliptin 5mg","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.","primaryOutcome":{"measure":"HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment","timeFrame":"Baseline and 24 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-0.03,"sd":0.06},{"arm":"Linagliptin 5 mg","deltaMin":-0.63,"sd":0.06}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":74,"countries":["United States","Canada","Denmark","Finland","France","Germany","Japan","Philippines","South Korea","Spain","Taiwan","Vietnam"]},"refs":{"pmids":["30632692","28636754","26224765"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":178},"commonTop":["Hypoglycaemia","Nasopharyngitis","Upper respiratory tract infection"]}}